RxDoctor Payments Data

Maximilian Garces, MD

Internal Medicine · Yorba Linda, CANPI 1588650436

Payments from drug & device makers

$1,958in general payments, 2019–2025

Across 105 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$295
  • Lilly USA, LLC$291
  • Novo Nordisk$257
  • Boehringer Ingelheim$157
  • GSK$146
  • Sanofi-aventis U.S. LLC$107
  • plus $706 from 15 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$1,93999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,958 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$101,453
Medicare patients
257
Services billed
945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate120$124,401
EliquisApixaban91$94,134
JardianceEmpagliflozin50$72,826
OzempicSemaglutide35$51,739
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,642
JanumetSitagliptin Phos/Metformin Hcl12$16,223
TradjentaLinagliptin16$16,134
Repatha SureclickEvolocumab22$16,119
Wixela InhubFluticasone Propion/Salmeterol77$12,038
Rosuvastatin Calcium458$10,554
Breo ElliptaFluticasone/Vilanterol13$9,233
Clonidine72$7,140
Atorvastatin Calcium540$6,210
Losartan Potassium464$5,714
Repatha SyringeEvolocumab15$5,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$18$140,624132 claims
PfizerEliquis$72$94,13491 claims
Boehringer IngelheimJardiance, Tradjenta$157$88,96066 claims
Novo NordiskOzempic$257$51,73935 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$146$37,81660 claims
AbbVieSynthroid$92$2,71831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Yorba Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →